Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
Part of paid clinical trials in Indianapolis, Indiana.
- Sponsor
- Hamid Sayar
- Study ID
- NCT01534260
- Phase
- PHASE1/PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- sorafenib, vorinostat and bortezomib — DRUGEscalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
Study Details
This research is being done because treatment options are very limited and usually unsuccessful for Acute Myeloid Leukemia (AML) in older individuals, or younger people with disease that has relapsed and/or proven resistant to standard therapy. Subjects are invited to participate in this study that will examine the use of three drugs called Sorafenib (Nexavar), Vorinostat (Zolinza) and Bortezomib (Velcade) for treating acute myeloid leukemia.
Key Dates
- Start date
- Feb 10, 2012
- Status verified
- Jul 2018
- Primary completion
- Aug 29, 2016
- Completion
- Feb 13, 2017
Study Design
- Enrollment
- 37 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: sorafenib, vorinostat and bortezomibEscalating cohorts of sorafenib, vorinostat and bortezomib
Primary Outcome Measure
Number of Patients With Dose Limiting Toxicity [ Time Frame: up to 9 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | - |
Find similar trials in Indianapolis, IN
By condition
By specialty
Related Studies
- Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesPHASE1/PHASE2 · Recruiting · CellCentric Ltd. · Atlanta, Georgia
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsPHASE3 · Recruiting · Children's Oncology Group · Birmingham, Alabama
- The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group StudyPHASE1/PHASE2 · Recruiting · PedAL BCU, LLC · Birmingham, Alabama
- Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)PHASE3 · Recruiting · PedAL BCU, LLC · Phoenix, Arizona